Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...

Novo Nordisk’s (NVO) semaglutide is a GLP-1 weight loss drug marketed as three separate brand name medications, Ozempic, Wegovy, and Rybelsus. Novo’s Wegovy competes with Eli Lilly’s (LLY) Zepbound.

Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.

Novo Nordisk NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Brownstein and his team noted that women and adults aged 66 to 75 saw the largest decreases in obesity. People living in the ...

The Biden administration has called for Medicare and Medicaid to expand coverage of weight-loss drugs for people struggling ...

The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss ...

GLP-1 agonists have taken the pharma world by storm, and Novo Nordisk has been at the forefront of it all thanks to ...

Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...

Dietitians explain whether rice water for weight loss really works. Discover how to make 'rice-zempic' and what to know ...